Results 21 to 30 of about 12,515 (211)
BMC Cancer, 2010 Background About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST.
Jiang Ming +4 more
doaj +1 more source
Billion-years old proteins show the importance of N-lobe orientation in Imatinib-kinase selectivity [PDF]
arXiv, 2023 The molecular origins of proteins' functions are a combinatorial search problem in the proteins' sequence space, which requires enormous resources to solve. However, evolution has already solved this optimization problem for us, leaving behind suboptimal solutions along the way. Comparing suboptimal proteins along the evolutionary pathway, or ancestors,
arxiv
The price elasticity of Gleevec in patients with Chronic Myeloid Leukemia enrolled in Medicare Part D: Evidence from a regression discontinuity design [PDF]
arXiv, 2023 Objective To assess the price elasticity of branded imatinib in chronic myeloid leukemia (CML) patients on Medicare Part D to determine if high out-of-pocket payments (OOP) are driving the substantial levels of non-adherence observed in this population.
arxiv
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity
Turkish Journal of Hematology, 2015 Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.
Caterina Musolino +7 more
doaj +1 more source
Malignant stromal tumor of the stomach with giant cystic liver metastases prior to treatment with imatinib mesylate [PDF]
Vojnosanitetski Pregled, 2013 Introduction. Gastrointestinal stromal tumors (GISTs) are rare and account for 0.1%-3% of all gastrointestinal neoplasms. GISTs are most commonly located in the stomach (60%) and 20%-25% are malignant, with metastases involving the peritoneum or
Čolović Radoje +5 more
doaj +1 more source
Asian Pacific Journal of Tropical Biomedicine, 2016 Objective: To evaluate the effect of imatinib mesylate on cell viability, anti cancer effect through modulation of KAI1/CD82 gene expression in breast cancer MCF-7 cell line.
Seyed Ataollah Sadat Shandiz +9 more
doaj +1 more source
Jurnal Penyakit Dalam Indonesia, 2020 Introduction. The complete hematologic response is an integral part to achieve the complete cytogenetic response target and the major molecular response of imatinib mesylate therapy, although it does not determine the prognosis.
Ikhwan Rinaldi +1 more
doaj +1 more source
Evolutionary dynamics of imatinib-treated leukemic cells by stochastic approach [PDF]
, 2008 The evolutionary dynamics of a system of cancerous cells in a model of chronic myeloid leukemia (CML) is investigated by a statistical approach. Cancer progression is explored by applying a Monte Carlo method to simulate the stochastic behavior of cell reproduction and death in a population of blood cells which can experience genetic mutations.
arxiv +1 more source
NovoMol: Recurrent Neural Network for Orally Bioavailable Drug Design and Validation on PDGFRα Receptor [PDF]
arXiv, 2023 Longer timelines and lower success rates of drug candidates limit the productivity of clinical trials in the pharmaceutical industry. Promising de novo drug design techniques help solve this by exploring a broader chemical space, efficiently generating new molecules, and providing improved therapies.
arxiv
OncoImmunology, 2018 Several studies support the notion that the kinase inhibitor Imatinib mesylate exerts off-target effects on cells of the immune system. After our first report of continuous daily oral administration in subjects with relapsed/refractory neuroblastoma (NB,
Fabio Morandi +12 more
doaj +1 more source